NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Profit Margin

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) posts a profit margin of -3644.21% as of June 2026. That compares with -232.9% in the prior-year period — down 1464.7% year over year. That is below the sector sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s profit margin was -232.9%. The latest reading is -3644.21% — a 1464.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 21.34% is typical. NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s -3644.21% is lower that level. That is roughly 17175.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -3644.21% as of June 2026; use YoY and peer views to separate noise from signal.

Context for NAMSW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s other metric pages and overview cover the third.